Explainer · US
7-OH "gas-station kratom": what DEA's schedule I notice means
DEA has published a notice of intent to place 7-OH and mitragynine pseudoindoxyl above a set threshold in schedule I. The notice says the temporary order will be published on or after November 13, 2026. What 7-OH is, what the threshold covers, what the harm data show and where to get help.
Review type: research summary. This page summarises published research and product labels, cited below.
Short answer: 7-OH (7-hydroxymitragynine) is an opioid, and the FDA says it is not lawful in dietary supplements. It occurs only in small amounts in the kratom leaf, but tablets, gummies and liquid shots with concentrated 7-OH are sold in gas stations, smoke shops and online, often labeled as "kratom". On October 14, 2026, the Drug Enforcement Administration (DEA) published a notice of intent to place 7-OH and a related opioid, mitragynine pseudoindoxyl, in schedule I of the Controlled Substances Act when a product is above a set threshold. The notice says the temporary order will be published in the Federal Register on or after November 13, 2026. If you use these products, do not wait for the law to change: the risks described below already apply.
What 7-OH is, and how it differs from kratom leaf
Kratom (Mitragyna speciosa) is a tropical tree native to Southeast Asia. Its main alkaloid is mitragynine. The FDA says 7-OH makes up less than 2% of the total alkaloid content of natural kratom leaves, but has substantially greater mu-opioid receptor potency than mitragynine and than classical opioids such as morphine. DEA's notice adds that 7-OH can be made from mitragynine in a one-step chemical reaction, that it is also formed in the body as a metabolite of mitragynine, and that synthetic and naturally occurring 7-OH have identical structures.
Mitragynine pseudoindoxyl is a chemical rearrangement product of 7-OH. DEA describes it as a potent opioid with strong affinity for the mu-opioid receptor, and says the first confirmed appearance of it in consumer products was reported in 2024. A 2026 paper in the Journal of Addiction Medicine adds a further contrast: in a preliminary evaluation, the authors did not detect 7-OH in water decoctions made from freshly harvested, unprocessed leaves, one of the ways kratom is traditionally consumed in Southeast Asia, and they argue that US kratom-labeled products differ in chemistry from that tradition.
What the products look like
Hill and colleagues identified 304 semi-synthetic 7-OH and mitragynine pseudoindoxyl products on vendor websites between September 2024 and February 2025. Most (82.2%) were 7-OH-only products sold as chewable or sublingual tablets, shots or gummies; 14.5% combined 7-OH with mitragynine pseudoindoxyl and 3.3% contained mitragynine pseudoindoxyl only. Of the 7-OH-only products, 92.0% were advertised as "kratom", and products containing mitragynine pseudoindoxyl, alone or combined with 7-OH, almost uniformly were. Effect claims, most often focus or relaxation, appeared for 73.3% of products, pain and anxiety relief claims for 37.8% and drug claims for 12.5%. The mean cost per recommended dose was $3.97, and several product names alluded to prescription opioids. The authors declare that some of them have been paid consultants to the International Plant and Herbal Alliance and have served as expert witnesses in kratom cases.
The FDA has said it is particularly concerned about 7-OH products that may appeal to children and teenagers, such as fruit-flavored gummies and ice cream cones, and that products may not be clearly or accurately labeled for their 7-OH content.
What DEA's threshold covers
The October notice follows a letter from the Assistant Secretary for Health dated October 8, 2026. Under it, 7-OH and mitragynine pseudoindoxyl, alone or combined, would be controlled in schedule I when a product is either:
- greater than 1 mg per gram for solid powders, encapsulated material or other solid forms, or greater than 1 mg per milliliter for liquid preparations; or
- a product in which the mass of mitragynine divided by the mass of 7-OH, mitragynine pseudoindoxyl or the two combined is less than 100.
In other words, the notice would place these opioids in schedule I only above that threshold. DEA says both have "supposedly been found in trace amounts in some botanical kratom products", which is why the order stops at the threshold, and that this would allow certain products to remain on the market without schedule I controls. Neither HHS nor DEA has found these substances safe at below-threshold levels, and DEA still calls kratom, mitragynine and 7-OH drugs of concern. Once the order is issued, schedule I controls and civil and criminal sanctions apply to anyone who manufactures, distributes, imports, exports or possesses 7-OH or mitragynine pseudoindoxyl above the threshold, among other activities listed in the notice.
This is a new notice of intent, not an order. DEA published an earlier notice of intent on July 6, 2026 (91 FR 40917), based on a lower threshold provided by HHS in July 2025. The October 14 notice says DEA is withdrawing that July notice in a separate Federal Register document. HHS opened a public docket on that earlier proposed threshold, with the comment period extended to September 10, 2026. Under the temporary scheduling law, an order lasts two years and can be extended by up to one year while permanent scheduling proceedings are under way.
Mitragynine pseudoindoxyl is already controlled. A DEA temporary order effective August 26, 2026, until August 26, 2028, placed it, together with two other 7-OH-related substances, MGM-15 and MGM-16, in schedule I without a threshold. DEA says that order stays in effect until it expires or until a new temporary order is published and the August order is withdrawn, whichever comes first. The October notice says DEA intends to withdraw the mitragynine pseudoindoxyl order and replace it with the new threshold order.
It was never a lawful supplement
Scheduling is a new layer, not the first restriction. The FDA states that 7-OH is not lawful in dietary supplements, cannot be lawfully added to conventional foods, and that there are no FDA-approved drugs containing 7-OH. In July 2025 the FDA announced warning letters to seven companies selling 7-OH products and recommended scheduling. In December 2025 the US Marshals Service seized about 73,000 units of 7-OH products, valued at roughly $1 million, from three firms in Missouri. The FDA also says kratom itself is not lawfully marketed as a dietary supplement or food additive, and warns consumers not to use kratom because of the risk of serious adverse events, including liver toxicity, seizures and substance use disorder.
DEA's notice says ten states (Alabama, Arkansas, Connecticut, Indiana, Kansas, Louisiana, Massachusetts, Tennessee, Vermont and Wisconsin) have prohibited 7-OH consumption, and some others, such as Arizona, Colorado, South Carolina and Texas, limit 7-OH as a share of total alkaloid content.
What the harm data show
America's Poison Centers, in an August 12, 2025 advisory, reported 165 exposure cases involving 7-OH in 2025. Among people exposed to 7-OH alone, 35% had serious health problems and 67% were treated at a healthcare facility. Reported symptoms included nausea and vomiting, agitation, confusion, sweating, rapid heart rate, high blood pressure, trouble breathing, sleepiness or loss of consciousness, and seizures. Kratom exposure reports from January 1 to July 31, 2025 (1,690) had already passed the total for all of 2024.
DEA's notice cites further data. A February 27, 2026, query of the FDA Adverse Event Reporting System found 86 cases involving 7-OH, of which 79 were reported as serious, a category that includes death, and 9 of the 86 resulted in death. DEA's toxicology program has identified 7-OH in 85 overdose cases since 2019, 55 of them fatal, and samples often also contained other alkaloids or other drugs, such as fentanyl, benzodiazepines and ketamine. These reports show a signal, not a precise death toll: many cases involved more than one substance.
Individual cases make the dose problem concrete. In a case report published in Annals of Emergency Medicine in October 2026, a 42-year-old man was found dead at home after reportedly taking three tablets of a commercial 7-OH product and several beers. A remaining tablet contained 29 mg of 7-OH. The authors estimate he took about 87 mg, 19 to 87 times the 1 to 4.5 mg of 7-OH they estimate in a typical high dose of dried kratom leaf powder, and judged the findings most consistent with a fatal opioid-like toxidrome. A 2026 potency analysis estimated morphine milligram equivalent (MME) values, relative to morphine, of 4.3 for 7-OH and 4.8 for mitragynine pseudoindoxyl (geometric means), against 0.13 for mitragynine. Applied to commercial products, mean per-serving MME ranged from 2.7 for powders to 31 for tablets. Those authors work for a consulting firm and note that polypharmacy could not be ruled out in the adverse event reports they screened.
Dependence is a recurring theme. A 2026 case report from Hawai'i describes a woman who had used kratom to get off illicit opioids, developed tolerance, moved to 7-OH and was spending about $150 a day. Her withdrawal in hospital resembled opioid withdrawal, and she was treated with buprenorphine-naloxone. DEA's notice also lists a 2026 case of cardiopulmonary arrest in which the finding was naloxone reversal of opioid respiratory depression.
Our view
Calling these products "kratom" or "botanical" is misleading. A concentrated 7-OH tablet behaves like an unregulated opioid of unknown strength, and DEA's notice says the identity, purity and concentration of these products are often unknown, uncertain and inconsistent. Scheduling is aimed at the enriched products, but DEA says the threshold would let certain products stay on the market, and DEA and HHS say that is not a finding that they are safe. Do not buy 7-OH or mitragynine pseudoindoxyl products, and do not give them to anyone else. If you already use them every day, talk with a clinician about how to stop. A 2026 case report describes hospital withdrawal that resembled opioid withdrawal and was managed with buprenorphine-naloxone, and DEA's notice lists a 2025 case that needed inpatient buprenorphine for high-dose 7-OH withdrawal. Those are single cases, not a treatment guideline. SAMHSA's National Helpline, 1-800-662-4357, can provide a treatment referral.
Where to get help
- If someone has trouble breathing, is very sleepy or cannot be woken, or has a seizure, call Poison Help at 1-800-222-1222. America's Poison Centers lists these among effects reported after 7-OH use. If the person is not breathing, call 911.
- Poison Help: 1-800-222-1222, to report a bad reaction. America's Poison Centers also says to keep these products away from children.
- SAMHSA's National Helpline: 1-800-662-4357, a free, confidential, 24/7 treatment referral and information service in English and Spanish.
- Report a bad reaction to a 7-OH product through FDA MedWatch online, or call 1-800-332-1088 to request a reporting form.
FAQ
Is kratom being banned? Not by this notice. It targets 7-OH and mitragynine pseudoindoxyl above the threshold. The FDA's position remains that kratom is not lawfully marketed as a supplement, and state rules vary.
When does the 7-OH order take effect? DEA says the temporary order will be published on or after November 13, 2026. Check the Federal Register for the published order and its effective date.
Is a product labeled "kratom extract" safe? The label does not tell you. Hill and colleagues found most 7-OH products were advertised as "kratom", and the FDA says 7-OH products may not be clearly or accurately labeled.
Sources
These are the documents this page relies on.
- Schedules of Controlled Substances: Temporary Placement of 7-Hydroxymitragynine and Mitragynine Pseudoindoxyl Above a Specified Threshold in Schedule I (notice of intent), 91 FR 65370, October 14, 2026Drug Enforcement Administration (Federal Register 2026-20943)
- Schedules of Controlled Substances: Temporary Placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in Schedule I (temporary order), 91 FR 54948, August 26, 2026Drug Enforcement Administration (Federal Register 2026-17429)
- Hydroxymitragynine Above a Specified Threshold in Schedule I; Extension of Comment Period, 91 FR 55104, August 26, 2026Office of the Assistant Secretary for Health, HHS (Federal Register 2026-17409)
- FDA Takes Steps to Restrict 7-OH Opioid Products Threatening American Consumers, July 29, 2025US Food and Drug Administration
- FDA Issues Warning Letters to Firms Marketing Products Containing 7-Hydroxymitragynine, July 15, 2025US Food and Drug Administration
- FDA Seizes 7-OH Opioids to Protect American Consumers, December 2, 2025US Food and Drug Administration
- FDA and KratomUS Food and Drug Administration
- Hiding in Plain Sight: 7-OH ProductsUS Food and Drug Administration
- Health Advisory: Serious Illnesses Associated with 7-OH Use, August 12, 2025America's Poison Centers
- Hill K, Boyer EW, Grundmann O, Smith KE. De facto opioids: characterization of novel 7-hydroxymitragynine and mitragynine pseudoindoxyl product marketing. Drug Alcohol Depend. 2025;272:112701Drug and Alcohol Dependence (PubMed 40373645)
- Gerona R, Ellison R, Conners R, Bissessar R. Fatal opioid-like toxidrome associated with a 7-hydroxymitragynine kratom product. Ann Emerg Med. 2026 (online ahead of print, October 27, 2026)Annals of Emergency Medicine (PubMed 42949698)
- Heywood J, Farnham H, Jackson E, Steimel K, Brown S, Riordan A. Beyond kratom: concentrated 7-hydroxymitragynine and mitragynine pseudoindoxyl products, an MME potency assessment. Regul Toxicol Pharmacol. 2026;173:106272Regulatory Toxicology and Pharmacology (PubMed 42838255)
- Karunakaran T, Vicknasingam K, Chawarski MC. Kratom-labeled products in the US compared with traditionally consumed natural kratom in Southeast Asia. J Addict Med. 2026 (online ahead of print, October 20, 2026)Journal of Addiction Medicine (PubMed 42822000)
- Kiyokawa M, Chun A, Hsia C. Managing 7-hydroxymitragynine use disorder with buprenorphine-naloxone. Hawaii J Health Soc Welf. 2026;85(10):295-298Hawai'i Journal of Health & Social Welfare (PubMed 42857839)
- SAMHSA's National HelplineSubstance Abuse and Mental Health Services Administration